Patients with Idiopathic dilated cardiomyopathy class II to IV NYHA with ejection fraction <35% were selected for phase I clinical trial of bone marrow mononuclear cell delivery in the coronary arteries and followed for 6 months
Using bone marrow mononuclear cell in 24 patients with Idiopathic dilated cardiomyopathy